XML 129 R85.htm IDEA: XBRL DOCUMENT v3.22.4
Basis of preparation - Additional Information (Details)
vaccine_dose in Millions
 1 Months Ended 12 Months Ended
Jul. 31, 2020
vaccine_dose
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
EUR (€)
Dec. 31, 2020
EUR (€)
Disclosure of initial application of standards or interpretations [line items]        
Current contract liabilities   € 264,000,000 € 319,000,000 € 252,000,000
Contract liabilities   85,000,000 0  
Net sales   42,997,000,000 37,761,000,000 € 36,041,000,000 [1]
Percentage of entity's revenue (in percent)       5.00%
Collaboration agreement with GSK | US Government        
Disclosure of initial application of standards or interpretations [line items]        
Number of vaccine doses to be supplied | vaccine_dose 100      
Government grant recognised as deduction from development expenses   € 265,000,000 147,000,000 € 0
Argentina        
Disclosure of initial application of standards or interpretations [line items]        
Cumulative inflation rate over three years   100.00%    
Turkey        
Disclosure of initial application of standards or interpretations [line items]        
Cumulative inflation rate over three years   100.00%    
RUSSIAN FEDERATION        
Disclosure of initial application of standards or interpretations [line items]        
Net sales   € 674,000,000 € 575,000,000 € 641,000,000
Percentage of entity's revenue (in percent)   1.60%    
[1] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.